Atorvastatin reverses cardiac remodeling possibly through regulation of Protein Kinase D/Myocyte Enhancer Factor 2D activation in spontaneously hypertensive rats

Pharmacological Research

Volumn 61, Issue 1, 2010, Pages 40-47

  Geng, Jing ^a   Zhao, Zhuo ^b   Kang, Weiqiang ^a   Wang, Wei ^c   Zhang, Yun ^a   Zhiming, G E ^a  

^a SHANDONG UNIVERSITY   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

Author keywords

Atorvastatin; Cardiac remodeling; Myocyte Enhancer Factor 2D; Protein Kinase D

Indexed keywords

ATORVASTATIN; HYDROXYPROLINE; LIPID; MYOCYTE ENHANCER FACTOR 2D; PROTEIN KINASE D; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ECHOCARDIOGRAPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FIBROSIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPIDS; MALE; MYOCARDIUM; PROTEIN KINASE C; PYRROLES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; VENTRICULAR REMODELING;

EID: 73049085413     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.08.004     Document Type: Article

References (36)

1. Heineke J., and Molkentin J.D. Regulation of cardiac remodelling by intracellular signalling pathways. Mol Cell Biol 7 (2006) 589-599
2. Haworth R.S., Cuello F., Herron T.J., Franzen G., Kentish J.C., Gautel M., et al. Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function. Circ Res 95 (2004) 1091-1099
3. Avkiran M., Rowland A.J., Cuello F., and Haworth R.S. Protein kinase D in the cardiovascular system: emerging roles in health and disease. Circ Res 102 (2008) 157-163
4. Harrison B.C., Kim M.S., van Rooij E., Plato C.F., Papst P.J., Vega R.B., et al. Regulation of cardiac stress signaling by protein kinase D1. Mol Cell Biol 26 (2006) 3875-3888
5. Fielitz J., Kim M.S., Shelton J.M., Qi X., Hill J.A., Richardson J.A., et al. Requirement of protein kinase D1 for pathological cardiac remodelling. PNAS 105 (2008) 3059-3063
6. Bossuyt J., Wu X., Avkiran M., Martin J.L., Pogwizd S.M., and Bers D.M. CaMKII and PKD overexpression seen in heart failure maintains the HDAC5 redistribution from the nucleus to the cytosol. Circulation 114 (2006) I1-I54
7. Kim Y., Phan D., van Rooij E., Wang D.Z., McAnally J., Qi X., et al. The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. J Clin Invest 118 (2008) 124-132
8. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
9. Porter K.E., Turner N.A., O'Regan D.J., Balmforth A.J., and Ball S.G. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovasc Res 61 (2004) 745-755
10. Martin J., Denver R., Bailey M., and Krum H. In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol 32 (2005) 697-701
11. Patel R., Nagueh S.F., Tsybouleva N., Abdellatif M., Lutucuta S., Kopelen H.A., et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104 (2001) 317-324
12. Switzer B. Determination of hydroxyproline in tissue. J Nutr Biochem 2 (1991) 229-231
13. Li Z., Zhang T., Dai H., Liu G., Wang H., Sun Y., et al. Endoplasmic reticulum stress is involved in myocardial apoptosis of streptozocin-induced diabetic rats. J Endocrinol 196 (2008) 565-572
14. Tanaka Y., Nagai M., Date T., Okada T., Abe Y., Seki S., et al. Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 27 (2004) 865-875
15. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart. J Am Coll Cardiol 47 (2006) 332-337
16. Chen G.P., Yao L., Lu X., Li L., and Hu S.J. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats. Acta Pharmacol Sin 29 (2008) 1181-1186
17. Chen H.J., Yao L., Chen T.G., Yu M., Wang L.H., and Chen J.Z. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats. Chin Med J (Engl) 120 (2007) 1902-1927
18. Diwan A., and Dorn G.W. Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) 22 (2007) 56-64
19. Selvetella G., Hirsch E., Notte A., Tarone G., and Lembo G. Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence. Cardiovasc Res 63 (2004) 373-380
20. Kai H., Kuwahara F., Tokuda K., and Imaizumi T. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28 (2005) 483-490
21. Murdoch C.E., Zhang M., Cave A.C., and Shah A.M. NADPH oxidase-dependent redox signaling in cardiac hypertrophy, remodeling and failure. Cardiovasc Res 71 (2006) 208-215
22. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
23. Mason R.P., Walter M.F., and Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109 (2004) II34-II41
24. Varagic J., and Frohlich E.D. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 34 (2002) 1435-1442
25. Iwata M., Maturana A., Hoshijima M., Tatematsu K., Okajima T., Jackie R., et al. PKCε-PKD1 signaling complex at Z-discs plays a pivotal role in the cardiac hypertrophy induced by G-protein coupling receptor agonists. Biochem Biophys Res Commun 327 (2005) 1105-1113
26. Takano H., Zou Y., Hasegawa H., Akazawa H., Nagai T., and Komuro I. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid Redox Signal 5 (2003) 789-794
27. Alvarez M.C., Caldiz C., Fantinelli J.C., Garciarena C.D., Console G.M., Chiappe de Cinqolani G.E., et al. Is cardiac hypertrophy in spontaneously hypertensive rats the cause or the consequence of oxidative stress?. Hypertens Res 31 (2008) 1465-1476
28. Shioi T., Matsumori A., Kihara Y., Inoko M., Ono K., Iwanaga Y., et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ Res 81 (1997) 664-671
29. Hasegawa H., Yamamoto R., Takano H., Mizukami M., Asakawa M., Nagai T., et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 35 (2003) 953-960
30. Yu Y., Ohmori K., Chen Y., Sato C., Kiyomoto H., Shinomiya K., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 44 (2004) 904-913
31. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 24 (2004) 8374-8385
32. Haworth R.S., Roberts N.A., Cuello F., and Avkiran M. Regulation of protein kinase D activity in adult myocardium: novel counter-regulatory roles for protein kinase c epsilon and protein kinase A. J Mol Cell Cardiol 43 (2007) 686-695
33. McEneaney V., Harvey B.J., and Thomas W. Aldosterone rapidly activates protein kinase D via a mineralocorticoid receptor/EGFR trans-activation pathway in the M1 kidney CCD cell line. J Steroid Biochem Mol Biol 107 (2007) 180-190
34. Romero D.G., Welsh B.L., Gomez-Sanchez E.P., Yanes L.L., Rilli S., and Gomez-Sanchez C.E. Angiotensin II-mediated protein kinase d activation stimulates aldosterone and cortisol secretion in H295R human adrenocortical cells. Endocrinology 147 (2006) 6046-6055
35. Mullin M.J., Lightfoot K., Marklund U., and Cantrell D.A. Differential requirement for RhoA GTPase depending on the cellular localization of protein kinase D. J Biol Chem 281 (2006) 25089-25096
36. Fibbi B., Morelli A., Marini M., Zhang X.H., Mancina R., Vignozzi L., et al. Atorvastatin but not elocalcitol increases sildenafil responsiveness in spontaneously hypertensive rats by regulating the RhoA/ROCK pathway. J Androl 29 (2008) 70-84